Shareholders update

Serodus announced on January 2nd 2017 the very positive outcome of that SER150 study. The drug candidate was well tolerated and statistical significant improvement on a relevant biomarker for kidney function was found. Based on these findings Serodus is now preparing for a meeting with the US regulatory authorities (FDA), a so called pre-IND meeting. Here the continuous development strategy for SER150 will be discussed. 

2017-06-28 aksjonærbrev